Apixaban 5 mg tablets,Eliquis 5 mg tablets
Sponsors
Bio-innova Co., Ltd.
Conditions
Healthy subjects
Bioequivalence Apixaban 5 mgHealthy subjects
Bioequivalence Apixaban 5 mg tabletsHealthy volunteers, A Bioequivalence safety study
Bioequivalence Apixaban 5 mg tabletsThe study is conducted in healthy Thai human volunteers to prevented anticoagulant.
Bioequivalence Apixaban 5 mg tablets
Phase 1
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Apixaban 5 mg tablets relative to Eliquis 5 mg tablets, in healthy Thai volunteers under fasting condition
TCTR20230203002
Start: 2023-06-13Target: 26Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Apixaban 5 mg tablets, relative to ELIQUIS 5 mg tablets in healthy Thai volunteers under fasting condition
TCTR20230714002
Start: 2024-01-23Target: 26Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Apixaban Tablet 5 mg, relative to EliquisTM, in healthy Thai volunteers under fasting condition
TCTR20240715013
Start: 2025-01-07Target: 28Updated: 2026-08-03
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Apixaban 5 mg tablets relative to Eliquis 5 mg tablets in healthy Thai participants under fasting condition
Active, not recruitingTCTR20251209005
Start: 2026-02-27Target: 28Updated: 2026-08-03